Invented by the South Korean biotech company Rokit Healthcare, the devices have already been deployed in major research ...

New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User ...

Bio-Rad stock looks undervalued, boosted by its Sartorius stake, but headwinds and volatile guidance cap upside. Click here ...

The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc.

Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr.

Aviva Bio is advancing AVA-291 (d3-T) as a differentiated testosterone in a broad development program addressing multiple ...

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Horizon Space Acquisition II Corp. ("HSPT") (Nasdaq:HSPT), a publicly traded special purpose acquisition company, and SL Bio Ltd. ("SL Bio"), a clinical ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. The ...

NEW YORK, Aug. 29, 2025 /PRNewswire/ -- YD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ...

Your Smart Girl Story isn't just a blog - it's a credential. Whether you're a coach, designer, artist, or student, it proves you've been published, interviewed, and featured. Here's how to weave it ...

Enrolled first patient in global, randomized study of safusidenib with registrational intent for maintenance treatment of high-grade IDH1-mutant glioma Enrolled first patient in TRUST-IV phase 3 study ...